{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 39,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/15",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.74,
        "w": 0.47,
        "x": 0.5,
        "y": 0.16
      },
      "kind": "chart",
      "text": "Vision Gainers Analysis at Week 12 ≥ 15-Letter Gain OCS-01 (N=100) 27.4% P = 0.009 Vehicle (N=48) 7.5%",
      "attrs": {
        "x_axis_label": "ITT Population",
        "y_axis_label": "Percentage of Patients Gaining ≥ 15 ETDRS Letters From Baseline to Week 12"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "292935e2-6ed5-48d3-82ec-6bbb63bd2a3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.74,
        "w": 0.47,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "chart",
      "text": "Vision Gainers Analysis at Week 6 ≥ 15-Letter Gain OCS-01 (N=100) 25.3% P = 0.015 Vehicle (N=48) 9.8%",
      "attrs": {
        "x_axis_label": "ITT Population",
        "y_axis_label": "Percentage of Patients Gaining ≥ 15 ETDRS Letters From Baseline to Week 6"
      },
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82e50921-1638-45ce-8e52-4209b116a5b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.14,
        "x": 0.82,
        "y": 0.03
      },
      "kind": "image",
      "text": "Oculis",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69749b40-e808-4975-83e9-d0da759c3e66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.67,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "ETDRS, Early Treatment Diabetic Retinopathy Study; ITT, intention-to-treat. Data, analysis and conclusions are preliminary, and subject to change as full analysis is ongoing.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94f98e22-94d9-4c27-84ab-2784beee11aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.76,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "3-line (15 letter) improvement in BCVA deemed highly clinically relevant",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c4cfe8b-eb9e-474f-a5e9-ef199ca2d9f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.81,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": ">25% of OCS-01 Patients Achieve ≥ 3 Line Gain in BCVA at Weeks 6 & 12",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "040e6a95-e429-46d9-9a7c-0ec04fe2a04e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 16,
      "from": 10,
      "beatId": "912bef89-3aea-45e9-87d5-3a2c6a5b8187",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 10-16 present data and results for OCS-01 in DME.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 16,
      "from": 10,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "10d012c4-eada-47a2-8cbd-e97bee6ca528",
      "evidence": "Slides 10-16 provide evidence and proof for OCS-01's effectiveness.",
      "position": 2,
      "objective": "Present data and results for OCS-01 in DME",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.8,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}